HCP Live June 13, 2024
After a biosimilar introduction, the prices of the biologic products—namely, trastuzumab, infliximab, bevacizumab, adalimumab, filgrastim, and pegfilgrastim—were significantly reduced.
The price of biologics both globally and in the US significantly reduced following the introduction of biosimilars, a study found.1
Prior research showed biologics prices reduced after introducing biosimilars in the market.2 However, the studies analyzed this with insurance claims data, failing to show negotiations and discounts between healthcare providers and insurers. The new study, led by Hui-Han Chen, MHS, BS, from the UNC Eshelman School of Pharmacy at the University of North Carolina, used annual global sales in the IQVIA MIDAS® database to examine the price fluctuations after introducing biosimilars.1
“This analysis showed that the entry of biosimilars impacted the...